Abstract: Use of organic compounds containing the —ONO2 function, or inorganic compound containing the —NO group or compositions comprising said compounds to reduce the toxicity caused by drugs to the gastrointestinal and/or renal apparatus, said compounds being characterized in that they are nitric oxide NO donors i.e., when they are put into contact in vitro with cells of the vasal endothelium or platelets.

Abstract: Nitrate salts of antimicrobial agents for the preparation of antimicrobial medicaments, specifically antiviral, antifungal and antibacterial medicaments.

Abstract: Nitro-oxyderivative compounds or salts thereof having the following general formula (I): A-(B)b0-(C)c0-NO2 wherein: c0 is an integer and is 0 or 1, b0 is an integer and is 0 or 1, A=R-T1-, wherein R is the radical of an analgesic drug for the chronic pain, in particular for the neuropathic pain; B is such that its precursor is selected from anminoacids, hydroxyacids, polyalcohols, compounds containing at least one acid function; C is a bivalent radical containing an aliphatic, heterocyclic or aromatic radical.

Abstract: Use for the vasculopathy treatment of compounds or salts thereof, having the following general formula: A-(B)b0-(C)c0-NO2 wherein A is the radical of the precursor drug selected between the salicylic or acetylsalicylic acid, B and C are bivalent linking groups as defined in the invention.

Abstract: Nitric acid salts with medicines having an antihypertensive activity.

Abstract: Nitric acid salts with medicines active in the respiratory system pathology treatment.

Abstract: Use of the following groups of compounds or their compositions for the preparation of medicaments for the treatment of gastrointestinal tumors, such compounds having general formula: A-X1—NO2 or their salts, where A=R(COX)t and where t is an integer 0 or 1; X═O, NH, NR1c, where R1c is a linear or branched alkyl having from 1 to 10 C atoms; R is (IA) where t=1 and X1 is equal to —YO— where Y is a C1-C20 alkylene, C5-C7 cycloalkyl or oxyalkyl derivatives.

Abstract: The invention relates to solid dispersions of nitrate active principles in at least one polymer chosen from the group consisting of polyvinyl pynolidone, cellulose derivatives or polyethylene glycol, their production processes and pharmaceutical formulations including said dispersions.

Abstract: Use for the treatment of diseases having an inflammatory basis of compounds or salts thereof, having the following general formula (I): A-Xt-L-(W)p—NO2 wherein A contains the radical of a drug, Xt and W arc bivalent radicals, L, is a covalent bond or oxygen, sulphur, NRtc wherein Rtc is H or a C1-C5 linear or branched alkyl.

Abstract: Use for the diabetes treatment of compounds or salts thereof, having the following general formula (I): A-(B)b0—(C)c0—NO2 wherein A contains the radical of a drug having an antiiflammatory or analgesic activity, B is a bivalen: linking group wherein the precursor must meet the tests described in the application, C is a a bivalent linking group as defined in the invention.

Abstract: Nitric acid salts with medicines having an antihypertensive activity.

Abstract: Use in the incontinence of one or more of the following classes of drugs selected from the following: B) salified and non salified nitric oxide-donor drugs, of formula: A-X1—N(O)z, B′) nitrate salts of drugs used for the incontinence, and which do not contain in the molecule a nitric oxide donor group; C) organic or inorganic salts of compounds inhibiting phosphodiesterases.

Abstract: The present invention provides a new class of compounds presenting a high compatibility with tissues and organic fluids. Such new compounds are polysaccharides essentially formed of units of uronic acid and/or hexosamine, containing nitro groups —ONO2 covalently bonded to the saccharide structure. Preferably, the polysaccharides according to the invention are prevalently formed of disaccharide repeating units formed of uronic acid and hexosamine. These compounds, in psychological conditions, selectively release NO, allowing a reduction in the amount of NO needed to achieve a determined therapeutical effect. This result has been achieved by functionalizing polyssacchrides essentially formed of units of uronic acid and/or hexosamine, with subsituents containing a ONO2? group.

Abstract: Use in sex dysfunctions of one or more of the following classes of drugs selected from the following: B) Salified and not salified, nitric oxide-donor drugs, of formula A—X1—N(O)z, C) Organic or inorganic salts of compounds inhibiting phospho-diesterases.

Abstract: Organic or inorganic salts of compounds of general formula: A—X1—N(O)z for use as medicaments having anti-inflammatory, analgesic and antithrombotic activity, wherein A is R(COXu)t wherein t is 0 or 1; u is 0 or 1 and X is O, NH, NR1c wherein R1c us a C1-C10 alkyl and R is, for example, (Ia) wherein R1 is acetoxy, preferably in ortho position with respect to —CO— and R2 is hydrogen or acetylsalicylsalicylic acid derivatives; and X1 is the formula (B), Y being a ring containing at least one salified nitrogen atom.

Abstract: Compounds of the formula and use of the compounds as medicaments.

Abstract: Nitrate salts of antimicrobial agents for the preparation of antimicrobial medicaments, specifically antiviral, antifungal and antibacterial medicaments.

Abstract: The present invention relates to nitrate salts of compounds having therapeutic activity in bony disorders, such compounds being characterized in that they contain at least a reactive group capable of being salified with nitric acid.

Abstract: The present invention relates to nitric acid salts with medicines active in the respiratory system pathology treatment.

Abstract: Pharmaceutical compositions for the therapy and the prevention of ulcer and dyspepsia relapses comprising as essential components the following components a) and b): component a): one or more components selected from the conventional anti-ulcer products; component b): organic compounds containing the —ONO2 function, or inorganic compounds containing the —NO group, characterized in that they are NO nitric oxide donors.